Orion Oyj (OTCMKTS:ORINY) Short Interest Down 50.0% in March

Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 300 shares, a decline of 50.0% from the February 28th total of 600 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 1,400 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research lowered shares of Orion Oyj to a "hold" rating in a research report on Tuesday, February 4th.

Orion Oyj Price Performance

Shares of OTCMKTS:ORINY traded up $0.62 on Tuesday, reaching $29.97. 1,119 shares of the company were exchanged, compared to its average volume of 3,158. The company has a 50-day moving average of $28.07 and a 200-day moving average of $25.70. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. Orion Oyj has a 1-year low of $17.50 and a 1-year high of $30.57. The firm has a market cap of $8.46 billion, a price-to-earnings ratio of 23.79 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The company had revenue of $463.41 million during the quarter. Equities analysts forecast that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Orion Oyj Increases Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th will be issued a dividend of $0.4478 per share. The ex-dividend date is Monday, April 7th. This is a boost from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio is presently 24.00%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.